High-Affinity Antibody Production via B-Cell Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing antibodies, particularly monoclonal antibodies, face challenges in achieving high affinity binding to antigens, often requiring laborious mutation techniques and recombinant methods that are time-consuming and elaborate.
Innovation Solution
A method involving the selection and expansion of B-cell populations with enhanced BCL6 and anti-apoptotic nucleic acid expression to increase the average binding capacity and affinity of antibodies produced, allowing for the isolation and cultivation of high-affinity B-cells that maintain elevated antigen binding capabilities over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If laborious mutation techniques and recombinant methods are used to achieve high affinity binding, then antibody affinity can be improved, but the process becomes time-consuming and elaborate
Solution Approach 1:
The patent changes the biological parameters of B-cells by modulating transcription factor expression levels (BCL6, BLIMP1, XBP-1) and cytokine environment (IL-21, IL-4, IL-10) to directly generate high-affinity antibodies through natural selection and affinity maturation processes, avoiding time-consuming recombinant mutation techniques
Solution Approach 2:
The system allows B-cells to naturally undergo affinity maturation through controlled culture conditions that mimic germinal center reactions, enabling the cells to self-select and evolve high-affinity variants without external genetic manipulation
2Reliability
If B-cells are cultured with CD40L, IL-2 and IL-4 to activate B-cells, then B-cell activation occurs, but very little Ig is produced
Solution Approach 1:
The patent changes the cytokine parameter composition by adding IL-21 to the culture medium alongside CD40L, IL-2, and IL-4, which triggers plasma cell differentiation and high-level antibody secretion while maintaining B-cell activation
Solution Approach 2:
The system dynamically controls the differentiation state of B-cells by modulating transcription factor expression (BCL6 for maintenance, BLIMP1 for differentiation) and cytokine signals, allowing transition from activated B-cell to antibody-secreting plasma cell
3Quantity of substance
If B-cells differentiate into terminally differentiated plasma cells to produce high Ig secretion, then antibody production increases, but cell cycle arrest precludes long-term antigen-specific BCR-positive cell lines
Solution Approach 1:
The patent dynamically controls the differentiation state by modulating transcription factor expression levels, allowing B-cells to maintain an intermediate plasmablast-like state that combines high antibody secretion with continued proliferative capacity for long-term culture
Solution Approach 2:
The system changes the expression parameters of key transcription factors (maintaining BCL6 to prevent terminal differentiation, controlling BLIMP1 to regulate plasma cell program) to achieve a stable intermediate state with both high secretion and long-term viability
Data Source
AI summary
The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.